ARHGEF25

Across TCGA pan-cancer cohorts, ARHGEF25 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARHGEF25’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARHGEF25 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF25 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

LSCC, COAD, and LUAD are the cancer types where ARHGEF25 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF25 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	III,IV	−0.726	<.001	8	view →
COAD	Female	All	−1.514	<.001	7	view →
LUAD	Female	All	−0.656	<.001	7	view →
PDAC	All	III,IV	−1.014	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARHGEF25–LSCC

Open the LSCC breakdown →